{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:00:33Z","timestamp":1776099633876,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health, Labour and Welfare Policy Research Grant","award":["25GC2003"],"award-info":[{"award-number":["25GC2003"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Clinical trials have demonstrated the efficacy, rapid action, and safety of calcitonin gene related peptide-related antibody drugs for migraine prevention, and subcutaneous galcanezumab was launched in Japan in April 2021. However, the safety of this drug in pregnant migraine patients has not been demonstrated in humans, with evidence of safety available only from animal studies. We report 2 cases in which subcutaneous galcanezumab was administered continuously until the first and second trimesters of pregnancy, resulting in normal births without any complications for either the mother or child.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>The cases involved pregnant patients, aged 34 and 43, with long-standing migraines without aura.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Migraines without aura.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>They were administered galcanezumab until the fifth week and fifth month of pregnancy, respectively. After discontinuation of treatment, the increase in the frequency of the mothers\u2019 migraines remained mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Each mother safely gave birth to a baby boy, with acetaminophen administered as needed for the management of headaches. Subsequent checkups showed that both mothers and their children were healthy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>The safety of galcanezumab administration in pregnant women has only been reported in scattered case reports, and further case studies are needed. It is considered necessary to continue to monitor newborns for the development of neurological abnormalities, including higher brain functions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000047895","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:01:06Z","timestamp":1772240466000},"page":"e47895","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Normal delivery following use of galcanezumab until the first and second trimesters of pregnancy: A report of 2 cases"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-6064","authenticated-orcid":false,"given":"Hisanao","family":"Akiyama","sequence":"first","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","article-title":"Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial.","volume":"75","author":"Skljarevski","year":"2018","journal-title":"JAMA Neurol"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial.","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"R3-20260413","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial.","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study.","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine.","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-022-01458-0","article-title":"Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.","volume":"23","author":"Hu","year":"2022","journal-title":"J Headache Pain"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2515816320932573","article-title":"Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial.","volume":"3","author":"Sakai","year":"2020","journal-title":"Cephalalgia Reports"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","article-title":"A long-term open-label safety study of galcanezumab in Japanese patients with migraine.","volume":"20","author":"Hirata","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial.","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.","volume":"21","author":"Silberstein","year":"2020","journal-title":"J Headache Pain"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A Controlled trial of erenumab for episodic migraine.","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine.","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s10194-024-01737-y","article-title":"CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society.","volume":"25","author":"Takizawa","year":"2024","journal-title":"J Headache Pain"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0333102420983292","article-title":"Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database.","volume":"41","author":"Noseda","year":"2021","journal-title":"Cephalalgia"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"3331024231158083","DOI":"10.1177\/03331024231158083","article-title":"Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase\u00ae.","volume":"43","author":"Noseda","year":"2023","journal-title":"Cephalalgia"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"3331024241273966","DOI":"10.1177\/03331024241273966","article-title":"Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: enhancing safety data.","volume":"44","author":"Elosua-Bayes","year":"2024","journal-title":"Cephalalgia"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"e70015","DOI":"10.1002\/pds.70015","article-title":"Monitoring pregnancies exposed to galcanezumab for migraine in a united states administrative claims database.","volume":"33","author":"Hoffman","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1177\/03331024211006827","article-title":"Letter to the editor regarding \u201cSafety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database\u201d.","volume":"41","author":"Kessler","year":"2021","journal-title":"Cephalalgia"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/03331024211006849","article-title":"Reply to the Letter to the Editor by Kessler Y et al. regarding the manuscript \u201cSafety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database.\u201d.","volume":"41","author":"Noseda","year":"2021","journal-title":"Cephalalgia"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/head.14393","article-title":"Gestational exposure to erenumab-The outcome of three pregnancies.","volume":"62","author":"Bonif\u00e1cio","year":"2022","journal-title":"Headache"},{"key":"R23-20260413","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/head.14305","article-title":"The use of erenumab for migraine prophylaxis during pregnancy: a case report and narrative review.","volume":"62","author":"Vig","year":"2022","journal-title":"Headache"},{"key":"R24-20260413","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s10072-020-04931-3","article-title":"Erenumab during pregnancy: a case report in a patient with chronic migraine.","volume":"42","author":"Fofi","year":"2021","journal-title":"Neurol Sci"},{"key":"R25-20260413","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/bfm.2019.0162","article-title":"Erenumab during breastfeeding.","volume":"14","author":"Henze","year":"2019","journal-title":"Breastfeed Med"},{"key":"R26-20260413","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s10194-024-01715-4","article-title":"Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase.","volume":"25","author":"Noseda","year":"2024","journal-title":"J Headache Pain"},{"key":"R27-20260413","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WCO.0000000000001372","article-title":"Migraine in women: a review.","volume":"38","author":"Ghadiri-Sani","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"R28-20260413","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1468-2982.2003.00480.x","article-title":"Course of migraine during pregnancy and postpartum: a prospective study.","volume":"23","author":"Sances","year":"2003","journal-title":"Cephalalgia"},{"key":"R29-20260413","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0404.2005.00350.x","article-title":"Headache and transient focal neurological symptoms during pregnancy, a prospective cohort.","volume":"111","author":"Ertresv\u00e5g","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"R30-20260413","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/bmj.39559.675891.AD","article-title":"Migraine in pregnancy.","volume":"336","author":"Goadsby","year":"2008","journal-title":"BMJ"},{"key":"R31-20260413","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10194-011-0329-1","article-title":"Headache and migraine during pregnancy and puerperium: the MIGRA-study.","volume":"12","author":"Kvisvik","year":"2011","journal-title":"J Headache Pain"},{"key":"R32-20260413","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G.","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"R33-20260413","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:01:40Z","timestamp":1776096100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047895","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}